NATCO Pharma Limited’s Board approved the Unaudited Financial Results for Q3 FY26, reporting consolidated revenue of ₹705.4 Crore and Profit After Tax of ₹151.3 Crore. The Board declared a third interim dividend of ₹1.50 per share. Key management personnel, including the Chairman & Managing Director, were re-appointed for one year effective April 1, 2026. The Board also approved the incorporation of a wholly-owned subsidiary in Chile.
NATCO Pharma Q3 FY26 Financial Highlights
The Board of Directors of NATCO Pharma Limited, following their meeting on 12th February 2026, approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December 2025.
The key consolidated performance indicators reported were:
- Consolidated Total Revenue: ₹705.4 Crore for Q3 FY26 (versus ₹651.1 Crore for Q3 FY25).
- Consolidated Profit After Tax (PAT): ₹151.3 Crore for the quarter.
- EBITDA margin stood at 30.7%.
The standalone results show a Profit Before Tax of ₹1,252 million for the quarter and Total Comprehensive Income of ₹1,120 million.
Interim Dividend Declared
The Board declared the third interim dividend of ₹1.50/- (75%) per equity share of ₹2/- each for the financial year 2025-26. The record date for this dividend payment is fixed as Wednesday, 18th February 2026, with payment scheduled to commence from 26th February 2026.
Key Board and Management Decisions
Based on the recommendations of the Nomination and Remuneration Committee, the Board approved the re-appointment of several key managerial personnel for a period of one year, effective 1st April 2026:
- Sri Venkaiah Chowdary Nannapaneni as Chairman & Managing Director.
- Sri Rajeev Nannapaneni as Vice Chairman & Chief Executive Officer.
- Sri Potluri Sivaramakrishna Prasad as Director and Executive Vice President (Corporate Engineering Services).
- Dr. Donthineni Linga Rao as Director & President (Tech. Affairs).
All re-appointments are subject to shareholder approval via Postal Ballot.
Further personnel changes noted include:
- The Board took note of the superannuation of Mr. S. V. V. N. Appa Rao, Chief Financial Officer, effective end of business hours on 12th February 2026.
- Mr. Amit Parekh was appointed as the new Chief Financial Officer, effective 13th February 2026.
- Mr. Kalakuntla Srinivas Rao was appointed as Executive Vice President – Pharma Division, effective 12th February 2026.
Corporate Restructuring and Investments
The Board also approved the following strategic actions:
- Incorporation of a wholly owned subsidiary in Chile, NATCO Pharma Chile SPA, with an investment up to US$ 3,00,000.
- Re-constitution of the Environmental, Social and Governance (ESG) Committee and the Risk Management Committee, effective 13th February 2026.
Segmental Performance Snapshot (Consolidated Revenue in ₹ Crore)
The segment breakdown for Q3 FY26 highlights the relative contributions:
| Business Segment | Q3FY26 (₹ Crore) | Q3FY25 (₹ Crore) |
|---|---|---|
| Active Pharmaceutical Ingredients (API) | 64.3 | 66.6 |
| Domestic Formulations | 119.8 | 96.1 |
| Formulations export (Incl. profit share and subs) | 421.4 | 285.8 |
| Crop Health Sciences (CHS) | 28.5 | 15.1 |
Details concerning the Associate Company, Adcock Ingram Holdings Ltd., showed a profit pick-up for NATCO amounting to ₹10.90 Crore for the relevant period after accounting for amortization.
Auditor Review Conclusion
The statutory auditors, BSR and Co Chartered Accountants, issued an unmodified review report on both the consolidated and standalone financial results for the period, confirming compliance with Ind AS 34.
Source: BSE
